Last updated: February 25, 2026
What is the Drug and Its Market Context?
NDC 42571-0357 is identified as VYEPTI (eptinezumab), a monoclonal antibody indicated for the preventive treatment of migraine in adults. Approved by the FDA in February 2020, VYEPTI is part of the calcitonin gene-related peptide (CGRP) inhibitor class, used specifically for episodic and chronic migraine prevention.
VYEPTI's mechanism involves intravenous administration every 3 months, targeting migraine pathophysiology directly.
Market Size and Growth Drivers
Prevalence of Migraine
- Approximately 39 million adults in the U.S. suffer from migraines.
- Around 18% of women and 6% of men experience this condition.
Market Segments
- Chronic migraine (≥15 headache days/month): ~8 million Americans.
- Episodic migraine (<15 headache days/month): Remaining migraine sufferers.
Key Demand Factors
- Increasing awareness of CGRP inhibitors.
- Annual growth in migraine preventive treatments estimated at 10-15% in the U.S.
- Reimbursement landscape favoring newer biologics due to efficacy and dosing convenience.
Competitive Landscape
- Erenumab (Aimovig) – First CGRP mAb, launched in 2018.
- Fremanezumab (Ajovy) – Approved in 2018.
- Galcanezumab (Emgalitys) – Launched in 2018.
- Eptinezumab (VYEPTI) – Entered market in 2020.
VYEPTI's intravenous route offers differentiation from subcutaneous options, appealing to certain patient populations guided by physician preference and insurance coverage.
Pricing and Reimbursement Environment
Current Pricing Data
- VYEPTI (NDC 42571-0357): Listed wholesale acquisition cost (WAC) of approximately $3,200 per dose.
- Each dose covers a three-month period, suggesting an annual list price of roughly $12,800.
Price Comparison to Competitors
| Drug |
Route |
Dosing Frequency |
Estimated Annual Cost |
List Price per Dose |
| VYEPTI |
IV |
Every 3 months |
~$12,800 |
~$3,200 |
| Aimovig |
SC |
Monthly |
~$13,200 |
~$730/month |
| Ajovy |
SC |
Monthly or quarterly |
~$14,000 |
~$650–700/month |
| Emgalitys |
SC |
Monthly |
~$14,400 |
~$600/month |
VYEPTI's quarterly dosing simplifies administration but is priced similarly on an annual basis to other CGRP inhibitors.
Reimbursement Trends
Insurance coverage favors high-efficacy treatments. Cost-sharing varies by plan, but injectable biologics generally receive prior authorization, impacting market access.
Price Projections and Future Trends
Short-term Outlook (2023-2025)
- Price Stability: No significant downward pressure expected. High patient and provider familiarity with CGRP class supports sustained pricing.
- Market Penetration: Expected to increase with expanding indications and broader provider adoption.
- Cost Management: Insurers might negotiate discounts or formulary preferential positioning, potentially reducing effective patient costs.
Long-term Outlook (2026+)
- Competitive Developments: Entry of biosimilars or new biologics could pressure prices.
- Pricing Adjustments: Price erosion could occur as patents expire or generics enter the market.
- Innovation Impact: Transition towards oral agents or combination therapies could redefine market dynamics, influencing pricing strategies.
Policy Impact
- Potential pricing reforms targeting biologic drugs could impose price caps or value-based pricing models.
- Medicaid and Medicare policies could influence reimbursement rates, impacting net revenues.
Market Opportunities and Risks
Opportunities
- Growing adoption in both episodic and chronic migraine populations.
- Expansion into additional indications like medication overuse headache.
- Potential for value-based agreements with payers.
Risks
- Market saturation with multiple CGRP options.
- Regulatory or policy shifts affecting drug pricing.
- Patent challenges or legal disputes.
Key Takeaways
- VYEPTI remains competitively priced relative to oral and injectable CGRP inhibitors.
- Its intravenous administration route offers differentiation, but influences patient preference and market penetration.
- Annual revenue projections align with current list prices and expected growth in the migraine preventive segment.
- Pricing stability is anticipated short-term; long-term trends may see erosion due to generics or biosimilars.
- Market opportunities are driven by increasing prevalence and clinician familiarity, but competitive pressures exert price constraints.
FAQs
1. Will the price of VYEPTI decrease in the coming years?
Price erosion could occur with biosimilar entry or increased competition, but current projections assume stable pricing through 2025 unless policy changes intervene.
2. How does VYEPTI’s administration route affect its marketability?
The intravenous route simplifies dosing over three months but may deter patients preferring subcutaneous options. It appeals to providers favoring infusion settings.
3. Are there indications for VYEPTI beyond migraine prevention?
Currently, VYEPTI is approved solely for migraine. Expansion into other CGRP-related indications is under investigation but not yet authorized.
4. How does insurance reimbursement differ among CGRP inhibitors?
Reimbursement varies; injectable biologics like VYEPTI often require prior authorization, and patient cost-sharing depends on plan specifics. Formulary placement influences access.
5. What are the main competitors to VYEPTI?
Erenumab, Fremanezumab, and Galcanezumab, all subcutaneously administered CGRP inhibitors with similar efficacy profiles but differing in dosing and patient preference.
References
[1] U.S. Food and Drug Administration (FDA). (2020). VYEPTI (eptinezumab) Prescribing Information.
[2] IQVIA. (2022). Top Pharmaceuticals Market Data.
[3] EvaluatePharma. (2022). World Preview of the Pharmaceutical Market.
[4] Centers for Disease Control and Prevention (CDC). (2021). Migraine Statistics.
